News >

Immunotherapy Revolutionizes NSCLC, But Unanswered Questions Remain

Gina Columbus
Published: Monday, Apr 24, 2017

Edward B. Garon, MD

Edward B. Garon, MD

Immunotherapy has had a milestone impact in the field of non–small cell lung cancer (NSCLC). However, as more research unravels, investigators are unsure which set of combinations will likely have the most positive effect on their patients with advanced disease.

State of the Science Summit on Advanced Non–Small Cell Lung Cancer.

OncLive: What is the current role of immunotherapy in NSCLC?

Garon: Obviously, this is an area that has evolved very rapidly and we finally have sort of hit a point where things are stable. However, now it looks like things may change again on some level. Of course, we are awaiting future data. For the last couple of years, we have had approved agents directed against PD-1 and a PD-L1 inhibitor, atezolizumab (Tecentriq).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Publication Bottom Border
Border Publication